Overview

Cord Blood Transplantation for Patients With Cancer

Status:
Terminated
Trial end date:
2012-06-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to assess the rate of engraftment with combined haploidentical-cord blood transplantation in patients with pre-existing donor specific antibodies and in those with active disease.
Phase:
Phase 2
Details
Lead Sponsor:
University of Chicago
Treatments:
Antilymphocyte Serum
Busulfan
Fludarabine
Fludarabine phosphate
Melphalan
Vidarabine